Next Target for Antibe Therapeutics' Proprietary Hydrogen Sulfide Platform: Inflammatory Bowel Disease (IBD)|Dan Legault, CEO, Antibe Therapeutics Inc. 00:10:00

Share On Facebook Share On Twitter

Antibe Therapeutics updates its otenaproxesul program and corporate progress while aiming to target inflammatory bowel disease (IBD), leveraging its hydrogen sulfide platform for safer therapeutic solutions addressing inflammation across various medical conditions.

Recent Videos